- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00140075
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
May 24, 2011 updated by: Pfizer
Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years.
The study will also evaluate the side effects of both treatment combinations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
606
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Pfizer Investigational Site
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Pfizer Investigational Site
-
-
California
-
Bakersfield, California, United States, 93309
- Pfizer Investigational Site
-
Berkeley, California, United States, 94704
- Pfizer Investigational Site
-
Fountain Valley, California, United States, 92708
- Pfizer Investigational Site
-
Fountian Valley, California, United States, 92708
- Pfizer Investigational Site
-
Gilroy, California, United States, 95020
- Pfizer Investigational Site
-
Poway, California, United States, 92064
- Pfizer Investigational Site
-
Soquel, California, United States, 95073
- Pfizer Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80907
- Pfizer Investigational Site
-
-
Florida
-
Jacksonville, Florida, United States
- Pfizer Investigational Site
-
Jacksonville, Florida, United States, 32224
- Pfizer Investigational Site
-
Kissimmee, Florida, United States, 34741
- Pfizer Investigational Site
-
Lake Worth, Florida, United States, 33461
- Pfizer Investigational Site
-
Lecanto, Florida, United States, 34461
- Pfizer Investigational Site
-
Miami, Florida, United States, 33176
- Pfizer Investigational Site
-
Miami Shores, Florida, United States, 33138
- Pfizer Investigational Site
-
Port St. Lucie, Florida, United States, 34952
- Pfizer Investigational Site
-
Tampa, Florida, United States, 33607
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Pfizer Investigational Site
-
Macon, Georgia, United States, 31201
- Pfizer Investigational Site
-
-
Illinois
-
Belleville, Illinois, United States, 62226
- Pfizer Investigational Site
-
Skokie, Illinois, United States, 60076
- Pfizer Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Pfizer Investigational Site
-
New Orleans, Louisiana, United States
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Pfizer Investigational Site
-
Baltimore, Maryland, United States, 21236
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Pfizer Investigational Site
-
-
Michigan
-
Harper Woods, Michigan, United States
- Pfizer Investigational Site
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Pfizer Investigational Site
-
Jackson, Mississippi, United States, 39202
- Pfizer Investigational Site
-
-
New Jersey
-
Mt. Holly, New Jersey, United States, 08060
- Pfizer Investigational Site
-
Willingboro, New Jersey, United States, 08046
- Pfizer Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Pfizer Investigational Site
-
-
New York
-
Brooklyn, New York, United States, 11235
- Pfizer Investigational Site
-
Great Neck, New York, United States, 11021'
- Pfizer Investigational Site
-
Staten Island, New York, United States, 10310
- Pfizer Investigational Site
-
-
North Carolina
-
Burlington, North Carolina, United States, 27216
- Pfizer Investigational Site
-
Greenville, North Carolina, United States, 27854
- Pfizer Investigational Site
-
Raleigh, North Carolina, United States, 27607
- Pfizer Investigational Site
-
-
Oklahoma
-
Lawton, Oklahoma, United States, 73505
- Pfizer Investigational Site
-
Oklahoma City, Oklahoma, United States, 73104
- Pfizer Investigational Site
-
-
Pennsylvania
-
Lemoyne, Pennsylvania, United States, 17043
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, United States, 19106
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States
- Pfizer Investigational Site
-
Columbia, South Carolina, United States, 29201
- Pfizer Investigational Site
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Pfizer Investigational Site
-
Knoxville, Tennessee, United States, 37923
- Pfizer Investigational Site
-
-
Texas
-
Corpus Christi, Texas, United States, 78412
- Pfizer Investigational Site
-
Tyler, Texas, United States, 11937
- Pfizer Investigational Site
-
-
Virginia
-
Arlington, Virginia, United States, 22205
- Pfizer Investigational Site
-
Portsmouth, Virginia, United States, 23704
- Pfizer Investigational Site
-
Richmond, Virginia, United States, 23226
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53209
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Breast Cancer Stage T1-3, N1, M0
- Suitable candidate for anthracycline-containing adjuvant chemotherapy
Exclusion Criteria:
- Evidence of residual tumor following surgery, or metastatic disease
- Received prior therapy for breast cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: B
ET (8 cycles) T = docetaxel or paclitaxel |
Epirubicin = 75 mg/m2 per cycle Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Other Names:
|
Experimental: A
EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles T = docetaxel or paclitaxel |
Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2 Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease free survival at 3 years
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess safety in both treatment arms at 3 years
Time Frame: 3 years
|
3 years
|
Compare overall survival between the 2 treatment arms at 3 years
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2000
Primary Completion (Actual)
August 1, 2006
Study Completion (Actual)
August 1, 2006
Study Registration Dates
First Submitted
August 29, 2005
First Submitted That Met QC Criteria
August 30, 2005
First Posted (Estimate)
August 31, 2005
Study Record Updates
Last Update Posted (Estimate)
May 26, 2011
Last Update Submitted That Met QC Criteria
May 24, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Epirubicin
- Taxane
Other Study ID Numbers
- 378-ONC-0030-184
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma
-
Criterium, Inc.University of Colorado, Denver; NovartisTerminatedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Adenocarcinoma | Hepatocellular AdenocarcinomaUnited States
-
University of ChicagoCompletedGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Weill Medical College of Cornell UniversityMerck Sharp & Dohme LLC; Oncolys BioPharma IncNot yet recruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
Roswell Park Cancer InstituteUnited States Department of DefenseRecruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingGastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial AdenocarcinomaUnited States
Clinical Trials on Epirubicin with a Taxane
-
Lund University HospitalDanish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaboratorsRecruitingBreast Cancer | Triple Negative Breast NeoplasmsDenmark, Sweden
-
Jenny C. Chang, MDGE Healthcare; The Methodist Hospital Research InstituteWithdrawn
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisActive, not recruiting
-
Kolding SygehusSygekassernes Helsefond; Open Patient data Explorative Network; Development and... and other collaboratorsCompleted
-
University of ThessalyRecruiting
-
ART Fertility Clinics LLCCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedCorneal SwellingCanada
-
Case Comprehensive Cancer CenterCompletedBreast CancerUnited States
-
Shanghai Jiao Tong University School of MedicineRecruiting